Vonoprazan-Based Quadruple Therapy: A 92% Solution for Refractory H. pylori

For patients who have failed two, three, or even four rounds of Helicobacter pylori eradication therapy, a new class of acid-suppressing drug is quietly rewriting the treatment algorithm. Vonoprazan-based bismuth quadruple therapy is now delivering first-attempt cure rates above 92% in real-world populations — including those with heavy antibiotic resistance — and achieving rescue success where every previous regimen has failed. For a bacterium long regarded as one of the hardest to eradicate in modern gastroenterology, this represents a genuine paradigm shift.

The Scale of the Refractory H. pylori Problem

H. pylori infects approximately half the world's population and is responsible for the majority of peptic ulcer disease, chronic gastritis, MALT lymphoma, and non-cardia gastric cancer. The World Health Organization classifies it as a Group 1 carcinogen, placing it in the same category as tobacco and asbestos. Eradicating it is not optional — it is one of the few interventions in gastroenterology that demonstrably reduces a patient's lifetime cancer risk. Yet for the past fifteen years, our ability to do so has been steadily eroding. Standard first-line clarithromycin-based triple therapy, once reliable, now fails in around one in three Australian patients, and in some regions of the world the failure rate exceeds 50%. Second-line bismuth quadruple therapy rescues many, but a stubborn subset of patients remains infected even after multiple attempts. These are the patients who arrive in my clinic exhausted, frustrated, and understandably sceptical that anything will work.

Why Standard Therapy Is Failing

Two forces are driving the decline of conventional therapy, and they work in tandem. The first is rising antibiotic resistance. Clarithromycin resistance in Australia now sits above 20% in most surveillance data; levofloxacin resistance is climbing; and metronidazole resistance, though manageable, is ubiquitous. The second, less appreciated force is pharmacological. H. pylori is most vulnerable to antibiotics when the gastric environment is nearly neutral — around a pH of 6 to 7. At the acidic pH found in an untreated stomach, the organism enters a dormant, coccoid form in which antibiotics simply cannot reach or kill it. Eradication therefore depends not just on the antibiotics but on how thoroughly and reliably stomach acid is suppressed during the treatment course. This is where traditional proton pump inhibitors, or PPIs, show their limits.

Vonoprazan: A New Generation of Acid Suppression

Vonoprazan belongs to a new class of drug called potassium-competitive acid blockers, or P-CABs. Unlike PPIs, which must be activated in an acidic environment and whose effect is progressive and sensitive to meal timing, vonoprazan reversibly binds the gastric proton pump's potassium channel directly. The result is faster, stronger, and more consistent acid suppression from the very first dose. Within twenty-four hours of starting vonoprazan, the intragastric pH is typically held above 5 for more than 80% of the day — a degree of acid control that PPIs rarely achieve even after a week of twice-daily dosing. Vonoprazan is also unaffected by CYP2C19 polymorphisms, meaning that patients who are fast metabolisers — a group in whom PPIs are notoriously underpowered — achieve the same robust response as everyone else. This pharmacological advantage translates directly into better bacterial killing.

The Quadruple Regimen

The most successful vonoprazan-based quadruple therapy combines vonoprazan 20 mg twice daily, bismuth subcitrate 220 mg twice daily, tetracycline 500 mg four times daily, and metronidazole 500 mg three or four times daily, taken for 14 days. Some variants substitute amoxicillin and furazolidone or replace tetracycline with another nitroimidazole, depending on local resistance patterns. What unites the successful regimens is the combination of deep acid suppression, bismuth's direct bactericidal action and ability to disrupt biofilms, and antibiotics that remain broadly active even against clarithromycin- and levofloxacin-resistant strains. Bismuth matters enormously in refractory disease: it penetrates gastric mucus, coats the bacterial surface, and reduces the organism's ability to adhere to the gastric epithelium. When paired with potent vonoprazan-driven acid suppression, the antibiotics finally reach bacteria that are metabolically active and susceptible.

The Evidence: Hitting 92% in the Real World

The VQ-HP trial, a prospective randomised study published in Scientific Reports in 2024, enrolled 231 patients in a region with clarithromycin resistance above 30% and levofloxacin resistance above 40%. A 14-day course of vonoprazan-based bismuth quadruple therapy achieved eradication in 92.2% of patients by intention-to-treat analysis, 97.3% by modified intention-to-treat, and 99.1% by per-protocol. These are remarkable figures — substantially higher than anything PPI-based therapy has delivered in similar populations, and achieved in real patients with real resistance patterns rather than in carefully curated trial populations. A separate large-scale real-world study in over 600 patients reproduced the finding with eradication rates of 84–96% depending on analysis. For rescue therapy specifically, a 2025 multicentre randomised controlled trial published in Helicobacter showed that substituting vonoprazan for a PPI in bismuth quadruple therapy improved eradication in previously treatment-refractory patients by a clinically meaningful margin. The consistency of the signal across different geographies, resistance profiles, and study designs is what makes this evidence persuasive.

In the past, rescue treatment for H. pylori after multiple failures often felt like a coin toss. With vonoprazan-based quadruple therapy, that has changed. For the first time in a decade, I can look a multiply-failed patient in the eye and tell them we have a regimen that is genuinely likely to work.

Why It Works When Everything Else Has Failed

Refractory H. pylori infections are refractory for specific, identifiable reasons. Resistance is one, but it is not usually the dominant reason. Poor acid suppression, inadequate duration, non-adherence driven by side effects, and biofilm protection of the bacteria within gastric mucus are often equally important. Vonoprazan-based quadruple therapy addresses almost all of these simultaneously. The rapid onset and uniform potency of vonoprazan remove the variability of acid suppression. The inclusion of bismuth tackles biofilms and reduces the bacterial burden independent of antibiotic susceptibility. The 14-day duration gives time for coccoid forms to convert to actively dividing bacteria that can be killed. And because vonoprazan has fewer drug interactions than PPIs and often better gastrointestinal tolerance, adherence over two weeks tends to be better than with comparable PPI-based regimens. It is not a single magic bullet; it is the convergence of several overlapping improvements, each modest on its own, that produces the jump in eradication rates.

Who Should Be Considered for This Regimen

Vonoprazan-based bismuth quadruple therapy is particularly valuable for patients who have failed one or more previous courses of H. pylori therapy, patients with a documented clarithromycin- or levofloxacin-resistant strain, patients from high-resistance regions or with recent macrolide exposure, and patients who have been diagnosed with H. pylori-associated peptic ulcer, MALT lymphoma, or a family history of gastric cancer, in whom eradication on the first attempt is especially important. It is also a rational first-line option in Australia's current resistance landscape, where the days of empirical clarithromycin triple therapy working reliably are arguably over. Whether to deploy it first-line or reserve it for rescue is a decision best made with a gastroenterologist familiar with local resistance patterns and the nuances of P-CAB therapy.

Practical Considerations and Side Effects

Vonoprazan is generally well tolerated. The most common side effects are mild gastrointestinal upset, headache, and — as with any potent acid suppressant — a small risk of rebound acid hypersecretion after cessation. Long-term vonoprazan is not routinely recommended outside specific indications such as acid-peptic disease, Barrett's oesophagus, and severe reflux, but for a 14-day eradication course the safety profile is excellent. Tetracycline can cause nausea and oesophageal irritation and should be taken upright with plenty of water; metronidazole has well-known interactions with alcohol and should be avoided with any ethanol exposure during and for 48 hours after the course; bismuth blackens the tongue and stool harmlessly but can be alarming if patients are not warned in advance. Confirmation of eradication with a urea breath test or stool antigen test at least four weeks after therapy completion — and at least two weeks after any PPI or vonoprazan exposure — remains essential. A negative result is the gold standard, and without it, we simply do not know whether treatment has succeeded.

When to See a Specialist

If you have had one or more failed courses of H. pylori eradication, persistent dyspepsia despite apparent eradication, a family history of gastric cancer, or an H. pylori-associated ulcer or MALT lymphoma, you should be seen by a gastroenterologist rather than continuing empirical therapy in primary care. At Mater Private Hospital in Wollstonecraft, we offer resistance-guided H. pylori management, including endoscopic biopsy with susceptibility testing when appropriate, tailored vonoprazan-based quadruple regimens for refractory cases, and post-treatment confirmation testing. For patients referred from the North Shore, the Northern Beaches, and beyond, the combination of P-CAB technology with bismuth-based therapy is now the most effective weapon we have against this stubborn, carcinogenic, and increasingly resistant organism. If you are tired of being told that nothing else can be done, it is almost certainly time for a specialist review.